SCHEMBL3974210

SCHEMBL3974210

NNC(=O)c1occ(COC(=O)Nc2ccccc2)c1-c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 2/20 0.44
TDP1 Q9NUW8 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
ENPP2 Q13822 3/20 0.40
POLB P06746 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
MAPT P10636 2/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
TP53 P04637 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4244119 0.86 MGLL (0.44) MGLLTDP1NPC1RAB9ASMN1; SMN2
SCHEMBL3983320 0.82 TP53 (0.43) NPC1RAB9ASMN1; SMN2LMNAPOLB
SCHEMBL3985267 0.81 MGLL (0.44) MGLLTDP1NPC1RAB9ASMN1; SMN2
SCHEMBL3973472 0.78 GAA (0.41) RAB9ASMN1; SMN2MAPTGAATP53
SCHEMBL3977524 0.78 GCGR (0.36) MGLLTDP1NPC1RAB9ASMN1; SMN2
SCHEMBL3977272 0.75 TACR1 (0.43) RAB9ASMN1; SMN2POLBMAPTGAA
SCHEMBL3977739 0.72 GAA (0.43) RAB9AMAPTGAAMEN1KMT2A
SCHEMBL3975730 0.70 GAA (0.45) GAAMEN1KMT2A
SCHEMBL3976813 0.70 MGLL (0.63) MGLLNPC1RAB9ASMN1; SMN2ENPP2
SCHEMBL20236427 0.69 MAPT (0.60) MGLLNPC1RAB9APOLBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 MGLL 710/4885TDP1 3923/4885NPC1 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.